Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus HCAG versus IA for elderly acute myeloid leukemia after failed initial induction
ChiCTR-OPC-15006896Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of decitabine, idarubicin, cytarabine, homoharringtonine, aclarubicin and 1 more in acute myeloid leukemia (AML) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Complete remission rate, Partial remission rate and 3 more. Planned start Sep 2015; status: not yet recruiting.
02
Drugs
decitabineidarubicincytarabinehomoharringtonineaclarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OPC-15006896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15006896.